Background
Bayer Healthcare LLC held patents covering human Factor VIII conjugates — specifically, methods of linking Factor VIII (the blood-clotting protein whose absence causes Hemophilia A) to polyethylene glycol (PEG) to extend the protein’s half-life and reduce the frequency of injections required by patients. Baxalta Inc. and its partner Nektar Therapeutics developed Adynovate®, a PEGylated recombinant Factor VIII product that competed directly with Bayer’s product.
Bayer sued Baxalta for infringing its patents. A jury found infringement, awarded $155 million in reasonable royalty damages based on a 17.78% royalty rate applied to Baxalta’s $873 million in sales, and found that the infringement was willful. The district court denied Baxalta’s motion for judgment as a matter of law and entered judgment accordingly. Both parties appealed — Baxalta on infringement, damages, and willfulness; Bayer on claim construction and enablement cross-issues.
The Court’s Holding
The Federal Circuit affirmed the infringement and damages holdings but reversed the willfulness finding. On willfulness, Judge Stoll applied the standard established by the Supreme Court in Halo Electronics v. Pulse Electronics (2016), which requires “wanton, malicious, and bad-faith behavior” to support enhanced damages. The court held that Baxalta’s knowledge of Bayer’s patent and its own infringing conduct was necessary but not sufficient to establish willfulness. The record did not show that Baxalta deliberately copied Bayer’s technology or acted in bad faith; rather, Baxalta’s PEGylation program was developed independently, and the company had a reasonable basis for believing its product was non-infringing. The willfulness finding and any resulting enhanced damages award were reversed.
On the 17.78% royalty rate, the court affirmed. The expert had testified to a range of 5.1% to 42.4% rather than a single point estimate, and the trial court had excluded the expert’s attempt to specify 23.75% as the rate (based solely on the midpoint of the range). Nevertheless, the jury’s selection of 17.78% — a rate within the expert’s range — was supported by substantial evidence as drawn from the record as a whole. The Federal Circuit declined to require an expert to present a single specific royalty rate when the jury has substantial evidence within the range to choose from.
Key Takeaways
- Knowledge of a patent and knowledge that one’s product infringes that patent are necessary prerequisites to willful infringement, but they are not sufficient — the infringer must also have engaged in wanton, malicious, or bad-faith conduct.
- A defendant who independently developed its product and had a reasonable legal basis for believing its product was non-infringing is unlikely to meet the willfulness standard even if it later turns out to have infringed.
- Juries may select a reasonable royalty rate from within a range presented by a damages expert, even where the expert did not reduce that range to a single specific number, as long as substantial evidence supports the rate selected.
- An expert’s use of the Nash Bargaining Solution as the sole support for a specific royalty rate — without additional evidentiary basis — is inadequate and subject to exclusion.
Why It Matters
Bayer v. Baxalta provided important guidance on two frequently contested issues in patent litigation: when willfulness supports enhanced damages, and how courts evaluate royalty rate evidence. On willfulness, the decision reinforced the post-Halo standard: courts and juries should not treat awareness of a patent as sufficient to trigger the enhanced-damages risk. The infringer must have gone further, behaving in a manner that warrants the exceptional remedy of up to trebling. This matters particularly in the pharmaceutical and biotech industries, where large established companies routinely monitor competitors’ patents without that awareness rising to the level of bad faith.
On the royalty damages question, the court’s acceptance of a rate selected from within an expert’s range gave litigants some comfort that damages testimony need not always culminate in a point estimate, even as it left standing the trial court’s exclusion of midpoint-based single-number opinions. The case remains a useful benchmark for structuring royalty expert testimony and for defending against willfulness claims in the life sciences.